Massachusetts Eye and Ear Infirmary to evaluate Stem Cell Innovation's PluriCells for hearing research
Stem Cell Innovations, Inc. announced that the Company will collaborate with Massachusetts Eye and Ear Infirmary (MEEI). Under the material transfer agreement, MEEI will evaluate PluriCells for their capacity to form the human tissues implicated in hearing loss. In return SCI will receive a nonexclusive license to intellectual property generated using the PluriCells.
"This collaboration with MEEI is another example of our strategy to work with top research groups in the world to accelerate human stem cell research", said Stem Cell Innovations CEO Dr. James Kelly. "As our PluriCells do not fall under the Presidential ban, there is a lot of interest from the academic world to get access to our human pluripotent stem cell platform".
Stem Cell Innovations recently disclosed it has produced multiple lines of human pluripotent stem cells. According to the company, these PluriCell lines can be efficiently cultured in tissue culture plates without the use of feeder layers and can be efficiently differentiated into multiple cell-types, having the potential to aid in drug discovery and development.
Other news from the department science
